Skip to search formSkip to main contentSkip to account menu

ALVAC vaccine

Known as: ALVAC 
A derivative of the Canarypox Virus, ALVAC can infect mammalian cells but it can't replicate. Thus, it produces a self-limiting infection which does… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Viral Vaccines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
BACKGROUND The Thai Phase III Trial of ALVAC-HIV and AIDSVAX B/E showed an estimated vaccine efficacy (VE) of 31% to prevent… 
2011
2011
The cost-effectiveness of a modestly effective HIV vaccine in the United States.
2011
2011
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine
Background:HIV-specific T-cell-based vaccines have been extensively studied in both prevention and therapeutic settings, with… 
Review
2010
Review
2010
HIV-vaccines: lessons learned and the way forward
Abstract A safe and efficacious preventive HIV vaccine, as part of a comprehensive prevention program, remains among the highest… 
Highly Cited
2007
Highly Cited
2007
Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095…
HIV-specific T cell responses play a critical role in the control of infection. We evaluated the impact of immune-based… 
Highly Cited
2006
Highly Cited
2006
Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus…
ABSTRACT Transmission of human immunodeficiency virus type 1 (HIV-1) occurs primarily via the mucosal route, suggesting that HIV… 
Highly Cited
2004
Highly Cited
2004
Safety profile of recombinant canarypox HIV vaccines.
Review
2001
Review
2001
Therapeutic vaccines against melanoma and colorectal cancer.
Highly Cited
1998
Highly Cited
1998
Efficacy evaluation of prime–boost protocol: canarypoxvirus‐based feline immunodeficiency virus (FIV) vaccine and inactivated FIV‐infected cell vaccine against heterologous FIV challenge in cats
Objective:To evaluate the immunogenicity and prophylactic efficacy of immunization schemes employing a recombinant canarypoxvirus… 
Highly Cited
1996
Highly Cited
1996
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys.
The efficacy of a recombinant human immunodeficiency virus (HIV) type 2 canarypox (ALVAC HIV-2) vaccine candidate given alone or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)